TROW — T. Rowe Price Group, Inc.

Sentiment is neutral-to-cautious and the price action reinforces it. As of 2026-09-13 the stock was -3.18% over one week and -4.60% over one month even though August AUM rose to $1.90T from $1.87T in July, because the market is focused on the -$7.9B of August net outflows and -$6.5B in Q2 2026, not on market-driven AUM appreciation. The Q2 print itself was fine (adjusted EPS $2.57 vs $2.52 consensus on $1.91B revenue), but analysts remain pinned at a Hold consensus with 24 holds and 6 sells against 8 buys and zero strong buys, and an average target of ~$113.50 that implies barely 7% upside. The Anthropic AI expansion and the F/M Investments acquisition are directionally positive but too small so far to change the flow narrative.

Revenue has ground higher with market-driven AUM: quarterly revenue moved from $1.67B in Q3 2023 to $1.91B in Q2 2026, with TTM revenue of ~$7.59B up ~7.0% YoY. But the growth is lumpy and beta-driven rather than organic — Q2 2026 revenue of $1.907B was +10.7% YoY largely on market appreciation, not net new business (Q2 net outflows of $6.5B; August 2026 outflows of $7.9B). The more important trend is margins: full-year operating margin fell from 32.9% in 2024 to 29.9% in 2025 as technology/AI, compliance and comp costs outran revenue, then partially recovered to 31.4% in H1 2026 versus 30.8% in H1 2025 — a stabilization, not yet a confirmed inflection. Reported EPS is noisy and partly flattered by non-operating items: Q2 2026 GAAP diluted EPS of $2.88 versus management's adjusted $2.57 implies roughly $0.31/share of investment gains, and Q2 2026 net income ($632.0M) actually exceeded operating income ($540.5M). Net read: modest, market-dependent top-line growth, a 2025 margin air-pocket that is stabilizing, and headline EPS running slightly ahead of the core business.

As of 2026-09-13, TROW traded at $106.29 on 10.65x TTM EPS of $10.381 — about a 22% discount to its own five-year average P/E of 13.65x, and a 25% discount on price/sales (3.0x vs a 4.01x five-year average). PEG is 0.936 and price/book is 2.07x with debt/equity of just 0.039. That discount is not obviously a mispricing: consensus next-FY EPS of $10.209 sits below FY2026's roughly $10.43, so the market is applying a low multiple to flat-to-down earnings. The offset is cash generation — TTM free cash flow of $2.05B is a 9.0% yield on the $22.77B market cap, and the 4.73% dividend consumes only about 53% of it, with essentially no long-term debt ($3.23B of cash at 2026-06-30). Verdict: cheap versus both its own history and the market, but 'cheap for a reason' rather than a mispricing — modestly undervalued, not a screaming bargain.

This is a value stock priced for stagnation. At $106.29 on 2026-09-13, the market is capitalizing roughly $10.3 of forward EPS at about 10.3x — well under the 13.65x five-year average — which means continued negative organic flows and fee-rate compression are already discounted. The asymmetry: if the Q3 report on/around October 30, 2026 shows outflows narrowing and any evidence the Anthropic AI rollout is bending the expense curve, the multiple normalizes toward 12-13x and the stock re-rates to roughly $124-$134 without needing any EPS growth at all. If flows instead widen, 2027 consensus EPS of $10.21 gives no earnings cushion and the 4.73% dividend becomes the entire return. You are being paid to wait; you are not being paid for unlimited patience.

As of 2026-09-13, TROW's RSI(14) was 32.17 — close to, but not through, the classic 30 oversold threshold. Price of $106.29 sat 3.81% below its 20-day SMA (about $110.5) and 6.77% below its 50-day SMA (about $114.0), but 2.37% above its 200-day SMA (roughly $103.8) — a short-term downtrend inside a still-intact longer-term uptrend (six-month return +19.98% versus -3.06% over three months and -4.60% over one month). Short-term momentum is deteriorating but not washed out; RSI in the low 30s with price above the 200-day is a 'watch' signal, not a buy signal. The better entry setups are either a successful retest of the 200-day near $104 with RSI pushing into the mid-20s, or a reclaim of the 50-day near $114 on volume.

• Rate policy: elevated rates keep money-market and fixed-income AUM elevated ($225B by August 2026) but simultaneously accelerate the secular rotation from active to low-cost passive vehicles — the core structural problem for TROW's equity franchise.
• Equity-market beta: revenue is a direct function of AUM, so a market drawdown hits revenue with a lag; the stock's 1.48 beta understates how much of the P&L is market-linked.
• Fee compression: industry-wide downward pressure on management fee rates means AUM must grow just to hold revenue flat, and TROW's fee rate is a key swing factor each quarter.
• Technology/AI cost cycle: enterprise gen-AI buildouts (the expanded Anthropic Claude deployment) plus compliance and digital infrastructure spend lifted the expense base enough to compress 2025 operating margin ~300bp to 29.9%; the payoff is unproven.
• Retirement/DC flows: the target-date franchise and customized retirement solutions remain a genuine structural tailwind against otherwise negative organic growth.

• Q3 2026 earnings on or around October 30, 2026 — the numbers that matter are net flows (Q2 2026 -$6.5B, August 2026 -$7.9B), the realized management fee rate, and any early cost-efficiency evidence from the Anthropic AI deployment.
• Monthly AUM updates for September and October 2026 — low-cost, high-frequency reads on whether market gains are still masking organic client leakage.
• Closing and integration of the announced F/M Investments acquisition plus the broader active-ETF, SMA and securitized-credit rollout — management's main hope for offsetting core outflows.
• Continued equity market appreciation: AUM was $1.90T at August 2026 (up from $1.87T in July), so crossing $2T would mechanically lift revenue and could shift sentiment.
• Any stabilization in 2027 consensus EPS (currently $10.209, below FY2026's ~$10.43) — the current low multiple has essentially no earnings-growth support, so a positive revision cycle would be the cleanest re-rating trigger.

• Organic outflows look structural rather than cyclical: -$6.5B in Q2 2026 and -$7.9B in August 2026 mean essentially all top-line growth is market beta, not net new business.
• 2027 consensus EPS of $10.209 is below FY2026's ~$10.43, so the entire bull case depends on multiple re-rating rather than earnings growth.
• Equity-market drawdown risk: with a 1.48 beta and AUM-linked revenue, a market correction hits both earnings and the multiple; the 200-day SMA near $104 is the first technical line to break.
• Earnings quality: Q2 2026 GAAP EPS of $2.88 versus adjusted $2.57 means roughly $0.31/share came from non-operating investment gains, and operating income of $540.5M was well below net income of $632.0M.
• Fee-rate compression outrunning AUM growth, compounded by the risk that AI and technology spend raises the cost base without delivering visible operating leverage.
• Scale mismatch on the growth pivots: active ETFs, private markets/OHA and the F/M acquisition are still rounding errors against a ~$1.9T asset base and may not offset legacy active equity outflows.

TROW is a genuinely cheap, essentially debt-free, 4.73%-yielding cash machine — $2.05B of TTM free cash flow against a $22.77B market cap is a 9.0% FCF yield, the dividend consumes only about half of that, and H1 2026 operating margin stabilized at 31.4% (+60bp YoY versus H1 2025). But it is not a growth story: Q2 and August 2026 both saw net outflows, 2027 consensus EPS of $10.21 is below FY2026's ~$10.43, and the 20% six-month gain looks more like multiple recovery than earnings acceleration. Own it for the dividend and a plausible re-rating toward 12x earnings; do not own it expecting organic growth to return. As of 2026-09-13, the technical setup (RSI 32.2, price 6.8% below the 50-day) argues for patience over chasing.

Blended two approaches as of 2026-09-13: (1) an 11.0x justified P/E — below the 13.65x five-year average because organic flows are negative and 2027 consensus EPS of $10.209 is below FY2026's ~$10.43, but above the 10.65x trailing multiple because the balance sheet is debt-free and margins have stabilized — applied to a roughly $10.30 blended forward EPS, giving ~$113; and (2) an 8.25% target FCF yield applied to TTM free cash flow of $2.051B, implying a ~$24.9B equity value, or ~$116 per share on ~214.3M shares outstanding. Averaging the two methods gives ~$115, roughly 8% above the 2026-09-13 price of $106.29, before the 4.73% dividend.